To evaluate the neuroprotective properties of the sigma receptor 1 (R1) ligand, (ϩ)-pentazocine in an in vivo model of retinal neurodegeneration.
S igma 1 receptors (R1) are Ca 2ϩ -sensitive, ligand-operated receptor chaperones at the mitochondrion-associated endoplasmic reticulum (ER) membrane. 1 Originally, they were thought to be a subtype of opiate receptor, but it is clear now that R1 is pharmacologically distinct from other known receptors. Two types of sigma receptors (R1 and R2) have been identified 2 ; R1, the better characterized of the two, has been cloned from several species. [3] [4] [5] [6] [7] R1 cDNA predicts a protein of 223 amino acids (M r 25-28 kDa). 3 R1 has been implicated in neuroprotection. 8 -14 In the brain, where R1 is expressed abundantly, ligands for the receptor have been useful in attenuating neuronal loss in in vitro 9, 11 and in vivo models of acute neurodegeneration. 10, 13, 14 Over the past several years, R1 expression has been analyzed in ocular tissue, [15] [16] [17] [18] [19] [20] [21] including the retina. 18 -21 RT-PCR analysis amplified R1 in neural retina and the RPE-choroid complex. In situ hybridization studies revealed abundant expression of R1 in the ganglion cell layer (GCL), inner nuclear layer (INL), inner segments of photoreceptor cells, and RPE cells. 18 Immunohistochemical analysis confirmed these observations. Recent studies in which primary cultures of mouse Müller cells were used localized R1 to the ER and nuclear membranes. 21 These cells and other retinal cell types demonstrate robust R1 binding activity with an apparent K d of ϳ25 nM. 21 The promising evidence of neuroprotection by R1 ligands in studies of brain tissue coupled with the finding that R1 is expressed in retina led us to explore the usefulness of ligands for R1 in retinal degeneration. Our initial studies were performed in vitro using a ganglion cell line, RGC-5, 22 and subsequently using primary ganglion cells isolated from neonatal mouse retina. 8 These studies demonstrated that treatment of cells with (ϩ)-pentazocine, a highly-specific R1 ligand, led to marked attenuation of cell death induced by the excitotoxins glutamate and homocysteine. These findings suggested that in vivo neurodegenerative diseases of the retina, such as glaucoma and diabetic retinopathy, which result in progressive loss of retinal neurons, may be amenable to treatment with R1 ligands. Earlier studies, showing that R1 continues to be expressed in neural retina under hyperglycemic conditions and during diabetic retinopathy, 20 prompted analysis of neuroprotection in this disease.
Diabetic retinopathy, a leading cause of blindness, is characterized by loss of retinal neurons and disruption of vasculature. 23, 24 Patients with diabetes lose color and contrast sensitivity within 2 years of onset. 25, 26 Focal ERG (electroretinogram) analysis, which detects electrical responses of ganglion cells, reveals dysfunction of these cells early in diabetes. 27, 28 Analyses of retinal tissue samples from diabetic patients provide further support of an involvement of retinal neurons in diabetic retinopathy, including detection of several markers of apoptosis. 29 The neuronal death observed in humans has also been reported in rodent models. 30 Using the TUNEL assay, Barber et al. 30 analyzed the retinas of diabetic patients as well as the streptozotocin-induced rat model and observed significantly more apoptotic neurons in retinas of diabetic subjects than in those of control subjects. Similar results were observed by Bek 31 and Kerrigan et al. 32 Recently, two mouse models of diabetic retinopathy were described in which retinal neuronal loss was reported. 33, 34 Spontaneously arising diabetes has been reported in the Ins2 Akita/ϩ mouse, which has a point mutation of the Insulin2 gene leading to hyperglycemia and hypoinsulinemia in heterozygous mice by ϳ4 weeks. 35 In addition to increased retinal vascular permeability and an increase in acellular capillaries,
Ins2
Akita/ϩ mice demonstrate ϳ20% to 25% reduction in the thickness of the inner plexiform layer (IPL), ϳ16% reduction in the thickness of the INL, and ϳ25% reduction in the number of cell bodies in the retinal GCL. 33 Cells in the GCL are immunoreactive for active caspase-3 after 4 weeks of hyperglycemia, consistent with cell death by apoptosis. In an induced model of diabetes, mice made diabetic by multiple injections of the pancreatic toxin streptozotocin, but not maintained on insulin, demonstrated 20% to 25% fewer cells in the GCL by 14 weeks after the onset of diabetes. 34 Data obtained using the TUNEL assay and analysis of active caspase-3 suggested that these neurons die by apoptosis. Viability is compromised in these animals, and most animals die by 16 to 20 weeks after onset of diabetes. Given that retinal neurons die over a relatively short period in these two mouse models, they were ideal for assessing neuroprotection by the R1 ligand (ϩ)-pentazocine. A pilot study to test (ϩ)-pentazocine dosage was conducted in the streptozotocin-induced model and the comprehensive analysis of neuroprotection was performed in the Ins2 Akita/ϩ model.
MATERIALS AND METHODS

Animals
These studies adhered to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. For the pilot study to determine an effective (ϩ)-pentazocine dosage, 3-week old C57Bl/6 female mice, purchased from Harlan Sprague-Dawley (Indianapolis, IN), were made diabetic with streptozotocin, according to our published protocol.
34
C57BL/6J Ins2 Akita/ϩ mice were purchased from The Jackson Laboratory (Bar Harbor, ME).
Ins2
Akita/ϩ female mice were bred to wild-type male mice in the animal facilities of the Medical College of Georgia, in accordance with institutional policy for appropriate care and use of animals. Genotyping of Ins2 Akita/ϩ mice was performed per the protocol recommended by The Jackson Laboratory. Retinas of male and female mice were examined; however, only those of the males were used in the morphometric retinal analyses, because disease progression in females is slower and less uniform. 35 Diabetes onset was verified by measuring urine glucose with a urine strip test (Clinistix; Fisher Scientific, Pittsburgh, PA) and blood glucose with a blood glucose meter (Prestige Smart System; Home Diagnostics, Inc., Ft. Lauderdale, FL). Fasting blood glucose levels Ͼ250 mg/dL were considered diabetic. Diabetic animals were not maintained on insulin. Age-matched, nondiabetic wild-type mice were used as the control. All mice received food and water ad libitum and were maintained on a 12-hour light-dark cycle. Body weight and blood glucose were measured at the time of death ( Table 1) .
Administration of (؉)-Pentazocine
A total of 101 mice were used in these experiments: 12 were used in the pilot study assessing (ϩ)-pentazocine dosage in the streptozotocininduced diabetic model, and 89 were used to assess (ϩ)-pentazocine in the Ins2
Akita model. Mice were distributed over four groups: diabetic plus (ϩ)-pentazocine treatment, diabetic with no treatment, nondiabetic plus (ϩ)-pentazocine treatment, and nondiabetic with no treatment (Table 1) . At the time of diabetes onset (or comparable age in nondiabetics), the mice were injected intraperitoneally with (ϩ)-pentazocine (Sigma-Aldrich, St. Louis, MO) that had been dissolved initially in DMSO and diluted with 0.01 M PBS. For the streptozotocin-induced diabetic mice, (ϩ)-pentazocine was administered via intraperitoneal injection at two dosages: 0.5 mg ⅐ kg Ϫ1 or 1.0 mg ⅐ kg Ϫ1 three times per 
RT-PCR and Immunoblot Analysis to Detect R1
The neural retina was dissected from the remainder of the eye cup of
Ins2
Akita/ϩ and wild-type mice. Three to four eyes per group per experiment were pooled for analysis. For gene expression, total RNA was isolated (TRIzol reagent; Invitrogen, Carlsbad, CA). RT-PCR was performed with primer pairs specific for mouse R1 6 : 5Ј-CTC GCT GTC TGA GTA CGT G-3Ј (sense) and 5Ј-AAG AAA GTG TCG GCT GCT AGT GCA A-3Ј (antisense) (nucleotide position 315-333 and 572-593; expected PCR product size, 279 bp). 18S RNA was the internal standard. RT-PCR was performed at 35 cycles, with a denaturing phase of 1 minute at 94°C, an annealing phase of 1 minute at 59°C, and an extension of 2 minutes at 72°C. A 20-L portion of the PCR products were gel electrophoresed and stained with ethidium bromide. For protein identification, we performed immunoblot analysis to detect R1 protein in neural retinas according to our published method. 8 Protein samples were subjected to SDS-PAGE and transferred to nitrocellulose membranes, which were incubated with anti-R1 antibody (1:500) followed by incubation with HRP-conjugated goat anti-rabbit IgG antibody (1:3000). The proteins were visualized by using a chemiluminescence Western blot detection system. The membranes were reprobed with mouse monoclonal anti-␤-actin antibody (1:5000) as a loading control. The films were analyzed densitometrically, as described. 8 
Tissue Processing and Morphometric Analysis
The mice were killed by CO 2 asphyxiation followed by cervical dislocation. The eyes were removed immediately and oriented in OCT (Tissue-Tek; Miles Laboratories, Elkhart, IN), such that the plane of section included the temporal and nasal ora serrata. Left and right eyes were frozen slowly by immersion in liquid nitrogen (without fixation); 10-m-thick cryosections were prepared as described. 36 Cryosections were stained with hematoxylin and eosin (H&E) and used for systematic morphometric analysis with a fluorescence microscope (Axioplan2 equipped with HRM camera and the Axiovision 4.6.3 program; Carl Zeiss Meditec, Dublin, CA). Measurements included the thickness of the total retina, IPL, INL, outer plexiform layer (OPL), and the photoreceptor inner/outer segments. The number of rows of photoreceptor cell nuclei in the outer nuclear layer (ONL) was counted. The number of cell bodies in the GCL was quantified by counting cells from the temporal ora serrata to the nasal ora serrata and expressing the data as number of cells per 100-m length of retina. Sections analyzed were from the center of the eyeball, thus the optic nerve was visible. Three measurements were made on each side (temporal and nasal) of the optic nerve at 200-to 300-m intervals resulting in six measurements obtained per eye. Both eyes were analyzed in each mouse. In addition, the eyes of nine mice (three wild-type, three Ins2
Akita/ϩ , and three (ϩ)-pentazocine-treated Ins2
Akita/ϩ , age: 12 weeks) were enucleated and fixed for 1 hour at room temperature in 2% paraformaldehyde and 2% glutaraldehyde in 0.1 M cacodylate buffer in sucrose and postfixed for 1 hour with osmium tetroxide. Processing and embedding of tissue in resin (EMbed-812; Electron Microscopy Sciences, Hatfield, PA) was performed according to our published protocol. 37 
TUNEL Assay and Immunodetection of Vimentin, 4-Hydroxynonenal, and Nitrotyrosine
Retinal cryosections were subjected to a TUNEL assay (ApopTAG Fluorescein In Situ Apoptosis Detection Kit; Chemicon, Temecula, CA), according to the manufacturer's protocol. They were counterstained with DAPI dye, to label all nuclei. For immunohistochemical detection of vimentin, 4-hydroxynonenal, and nitrotyrosine, retinal cryosections were fixed for 10 minutes in 4% paraformaldehyde prepared in PBS, washed thrice in PBS for 5 minutes, and blocked for 1 hour (PowerBlock; Biogenx, San Ramon, CA). All procedures were performed at 4°C. Sections were incubated in a humidified chamber overnight at 4°C with either mouse anti-human vimentin monoclonal antibody (1:25; Chemicon), rabbit polyclonal anti-4-hydroxy-2-nonenal antibody (1:3000; Alpha Diagnostic, San Antonio, TX) or rabbit antinitrotyrosine polyclonal antibody (1:250; Chemicon). In control experiments, some sections were incubated with normal donkey serum instead of the primary antibody. For detection of the primary antibodies, the sections were washed three times in PBS for 5 minutes and incubated with either Oregon Green Alexa Fluor 488 -conjugated goat anti-mouse IgG (1:1000) to detect vimentin, or Alexa Fluor 555- Akita/ϩ mice (age, 8 weeks; 4 weeks diabetic) and agematched wild-type mice, which had been maintained in the absence or presence of 0.5 mg ⅐ kg Ϫ1 (ϩ)-pentazocine for 4 weeks. Proteins were subjected to SDS-PAGE, followed by immunoblot analysis with an affinity-purified antibody against R1 (M r ϳ 27 kDa) or ␤-actin (M r ϳ 50 kDa) (internal loading control). (D) Band density, quantified by densitometry, indicated that R1 protein levels were similar between wild-type and
Ins2
Akita/ϩ mice, and the levels were not altered by a 4-week treatment with (ϩ)-pentazocine. The ratio of the R1/␤-actin bands of the wild-type (ϩ/ϩ) mice was assigned an arbitrary unit of 1. 
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temporal ora serrata. In each experimental group, retinas of five mice were analyzed.
Statistical Analysis
Analysis of variance was used to determine whether there were significant differences in morphologic measurements and in the number of TUNEL-positive cells in diabetic versus nondiabetic, age-matched control mice, as well as in diabetic or age-matched, nondiabetic mice with no treatment versus diabetic mice treated with (ϩ)-pentazocine. The Tukey paired comparison test was the post hoc statistical test. Data were analyzed with commercial software (SPSS, ver. 14; SPSS, Chicago, IL). P Ͻ 0.05 was considered significant.
RESULTS
R1 Gene and Protein Expression in Retinas of
Ins2 Akita/؉ Mice
Before testing neuroprotective effects of (ϩ)-pentazocine, R1 mRNA and protein expression were analyzed in Ins2
Akita/ϩ mouse retinas (Fig. 1) . The expression levels were comparable to wild-type, suggesting that R1 is an available therapeutic target in the diabetic retina. These findings were similar to our previously published data showing that R1 is expressed in neural retina of the streptozotocin-induced diabetic mouse retina.
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Effects of Pentazocine on Neuronal Death in Diabetic Retinopathy
The dosage of (ϩ)-pentazocine used in the study with Ins2 Akita/ϩ was selected based on data from the pilot study of streptozotocin-induced diabetic mice. Histologic sections of retinas from streptozotocin-induced diabetic mice are shown in comparison to control and (ϩ)-pentazocine-treated mice (Fig. 2) . The diabetic mice had fewer cells in the GCL, but the retinal architecture was similar to that of the control. Streptozotocin-induced diabetic mice were administered various dosages of (ϩ)-pentazocine (Table 1) . At the 0.5-mg ⅐ kg Ϫ1 dosage, (ϩ)-pentazocine reduced cell loss in the GCL (Fig. 2B ) and reduced apoptotic neuron death (Fig. 2C) . Thus, this dosage was used in the comprehensive analysis of the effects of (ϩ)-pentazocine on retinopathy in the Ins2 Akita/ϩ mice.
Ins2
Akita/ϩ mice were injected intraperitoneally at diabetes onset (ϳ4-weeks of age) with 0.5 mg ⅐ kg -1 (ϩ)-pentazocine twice weekly for 22 weeks. The progression of changes in Ins2 Akita/ϩ retinas compared with wild-type over this time period is shown in Figure 3 . Wild-type mice had uniform thickness of layers throughout the central and midperipheral retina (Fig. 3A) . Ins2 Akita/ϩ mice had modest INL thinning at 7 weeks (Fig. 3B) and more dramatic INL cell dropout at 10 weeks (Fig. 3C) . By 17 to 25 weeks, there was marked INL and GCL cell loss in Ins2
Akita/ϩ mice (Figs. 3D-F) . The IPL, which is composed of synaptic processes of cells in the INL and GCL, was also thinner. The cell loss and misalignment of inner retinal layers resulted in a somewhat wavy appearance in some of the retinas of 17-to 25-week-old Ins2 Akita/ϩ mice. We found that Akita/ϩ mice were comparable to wild-type mice (Fig. 3J) Akita/ϩ mice (15.6 Ϯ 1.5 cells/100 m) were similar to those in wild-type (Fig. 3M) . Of note, (ϩ)-pentazocine-treated Ins2
Akita/ϩ mice remained hyperglycemic throughout treatment. Blood glucose levels were ϳ500 mg/dL (similar to untreated Ins2 Akita/ϩ mice) and were significantly higher than those in wild-type mice (104 -160 mg/dL; Table 1 ), suggesting that hyperglycemia per se may not be sufficient to trigger neuronal loss in diabetes.
Assessment of Neuronal Apoptosis and Cellular Stress
Neuronal apoptosis has been reported in Ins2
Akita/ϩ mouse retinas. 33 We determined the number of TUNEL-positive cells in retinas of (ϩ)-pentazocine-treated versus untreated Ins2
Akita/ϩ mice (Figs. 4A-C). There were significantly more TUNEL-positive cells in the GCL and INL in retinas of untreated mice than in those of treated and wild-type mice (Figs. 4D, 4E ), demonstrating robust neuroprotective effects of (ϩ)-pentazocine in vivo. To assess the effects of diabetes on Müller cells, we visualized the radial fibers by immunolabeling of the intermediate filament protein vimentin, a glial cell marker. 
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Akita/ϩ mouse retinas displayed disrupted, punctate labeling of fibers (Fig. 5B) 
whereas (ϩ)-pentazocine-treated
Ins2
Akita/ϩ mouse retinas had well-organized fibers comparable to wild-type retinas (Figs. 5A, 5C ). Given the major role of Müller cells in maintaining retinal structural integrity, the disruption of fibers may contribute to the progressive damage observed in diabetic retinas; treatment of Ins2 Akita/ϩ mice with (ϩ)-pentazocine preserved the radial organization. Reactive oxygen and nitrogen species have been implicated in the pathogenesis of diabetic retinopathy. 38 -40 We analyzed the levels of 4-hydroxynonenal and protein-nitrotyrosine, markers of lipid peroxidation and reactive nitrogen species, respectively, in retinas of Ins2 Akita/ϩ mice compared with wild-type and (ϩ)-pentazocine-treated Ins2 Akita/ϩ mice. There was increased immunodetection of these markers in Ins2
Akita/ϩ mice (Figs. 5E, 5H ). Treatment with (ϩ)-pentazocine (Figs. 5F, 5I ) decreased the levels and were comparable to wild-type (Figs.  5D, 5G ), suggesting that (ϩ)-pentazocine reduces oxidative and nitrosative stress in diabetic retina.
The cell loss quantified in the present study (Fig. 3) is consistent with that reported for Ins2 Akita/ϩ mice by Barber et al. 33 In that study, the eyes were fixed in 4% paraformaldehyde and were subjected to cryosection/tape-transfer methodology. The morphology of the retinas of wild-type and pentazocinetreated Ins2 Akita/ϩ mice in the present study was well-preserved; however, cryoembedding, especially without fixation, can have untoward effects on retinal morphology, particularly if the retina is degenerating. Cryoembedding retinal tissue retains antigenicity and thus is advantageous for detection of markers of apoptosis and cellular stress (as needed for data presented in Figs. 4, 5) ; however, it does not preserve retinal architecture structure as well as other histologic processing methods. Hence retinas of nine additional mice were fixed in a formaldehyde-glutaraldehyde solution and processed for embedding in resin (Embed 812; Electron Microscopy Sciences). Figure 6 shows representative images from these specimens. The retinas of wild-type mice were well organized, with the ganglion cells being evenly distributed and the INL of a uniform thickness (ϳ6 -7 rows, Fig. 6A ). Cells in both of these layers had lightly stained cytoplasm, and most had a plump, round shape. The retinas of the pentazocine-treated Ins2 Akita/ϩ mice had excellent morphology, an appearance similar to wild-type (Fig. 6D) . The retinas of the Ins2 Akita/ϩ mice showed somewhat improved morphology than was observed with cryosec- . 3) ; however, disruption in the INL-OPL interface continued to be evident (Fig. 6B, arrow) . Cells of the GCL had a variable appearance. Some were plump and round adjacent to others that were shrunken and darkly stained, indicative of cells that are dying. The INL of the Ins2 Akita/ϩ mice had approximately four to five rows of cells. There were noticeable gaps between many of the cells that were not observed in the wild-type mice or in the Ins2 Akita/ϩ mice treated with (ϩ)-pentazocine. These data of fixed retinal specimens are consistent with data obtained from the unfixed specimens and reflect cellular loss in the retinas of the Ins2 Akita/ϩ mice, which can be prevented by administration of (ϩ)-pentazocine.
DISCUSSION
This study represents the first report of the neuroprotective effects of the R1 ligand (ϩ)-pentazocine in an in vivo model of spontaneously arising retinopathy. The model we chose for our detailed analysis of the effects of (ϩ)-pentazocine, the Ins2 Akita/ϩ mouse, was an ideal animal in which to test neuroprotection because of the quantifiable loss of retinal neurons over a relatively short time (4 -5 months). 33 The observation that the R1 gene and protein continued to be expressed in the mutant mice indicated that the appropriate target for the (ϩ)-pentazocine treatment was available. (ϩ)-Pentazocine is widely regarded as a potent and highly specific R1 ligand based on pharmacologic studies. 41 It binds R1 with a very high affinity and is presumed to be an agonist for the receptor; however, because the actual signaling events associated with R1 activation have not been characterized, it is difficult to ascribe definitively an agonist or antagonist function to this ligand. It is for that reason that in the present study we did not test other compounds (i.e., presumed antagonists of R1), to demonstrate specificity of the effect. The most convincing molecular evidence that (ϩ)-pentazocine is specific for R1 comes from analysis of the R1 knockout mice (mR1 Ϫ/Ϫ mice) developed in the Montoliu laboratory. 42 Northern blot and Western blot analysis of multiple organs known to express R1 (liver, kidney, brain, and heart) revealed no specific mRNAs for the mouse R1 gene or protein in any of these organs in the homozygous (knockout mice), whereas expression was reduced by half in heterozygous compared with wild-type mice. When brain membranes from the mR1 Ϫ/Ϫ mice were analyzed in binding assays with [ 3 H](ϩ)pentazocine used as the radioligand, no binding activity in brain membranes was observed, and binding activity was reduced by half in heterozygous compared with wild-type animals (as shown in Fig. 3 of Ref. 42) . Therefore, we conclude that the effects of (ϩ)-pentazocine observed in the present study are due to effects on R1.
The biweekly exposure of the Ins2 Akita/ϩ mice to (ϩ)-pentazocine led to marked preservation of retinal structure. The morphology of the treated mice was excellent. The number of cells in the GCL in the (ϩ)-pentazocine-treated Ins2 Akita/ϩ mice was comparable to the number in the wildtype. The inner nuclear and plexiform layers were of a thickness comparable to those in the wild-type.
Of interest, the preservation of retinal architecture and reduction of neuronal apoptosis did not appear to be a direct function of decreased hyperglycemia, because the (ϩ)-pentazocine-injected Ins2
Akita/ϩ mice demonstrate marked elevation of blood glucose through the time of death. This finding is important and raises the question of whether retinal neuronal loss associated with diabetes involves hyperglycemia directly or whether it is due to complications secondary to hyperglycemia, such as oxidative stress. Our analysis of markers of cellular stress (4-hydroxynonenal, nitrotyrosine) showed a marked increase in expression in the Ins2 Akita/ϩ retinas, but a sharp quenching of these stress indicators in the presence of (ϩ)-pentazocine. These findings are interesting in light of reports that ligands for R1 can reduce NO production 13, 43, 44 and oxidative stress. 45 It is noteworthy that increased R1 binding activity was observed in vitro when retinal Müller cells were treated with NO donors and donors of reactive oxygen species. 21 The variable appearance of the mutant Ins2 Akita/ϩ retinas was intriguing and is reminiscent of the histologic features of retinas reported in studies of patients with diabetes 29, 38 in which ganglion cell loss is extensive and INL disruption and cell loss are substantial. The alteration in retinal organization suggested that the scaffolding of the retina may be compromised. The cells known to be involved in such organization are the Müller cells and disruptions of Müller glial cells have been reported in diabetic retinopathy. 39, 40 Our immunolabeling studies of vimentin, a Müller cell marker, showed punctate labeling in the Ins2
Akita/ϩ mouse retinas, but well-organized radial fibers in the (ϩ)-pentazocine-treated animals. It would be interesting in future studies to isolate Müller cells from the Ins2
Akita/ϩ and assess their myriad functions (e.g., transport activities), in the presence and absence of (ϩ)-pentazocine.
In summary, we found that the R1 ligand (ϩ)-pentazocine afforded robust protection against retinal degeneration observed in Ins2
Akita/ϩ mice, a mouse model of spontaneously arising diabetes. The cell loss, neuronal apoptosis, marked disruption of retinal layers, and increased oxidative stress were prevented by treatment with (ϩ)-pentazocine. The results are encouraging, because ligands for R1 are already used clinically in the treatment of other diseases, including neuropsychiatric diseases (schizophrenia, depression, and cognitive disorders). 46 Promising results from the Bucolo laboratory in work involving acute injury-induced models in rat retina and new forms of R1 ligands suggest that R1 is a very attractive target for therapeutic intervention of retinal disease. 47 It remains to be determined whether other models of spontaneously arising nonacute retinal degeneration-for example, models of glaucoma-will respond positively to (ϩ)-pentazocine. In addition, it is not known whether the treatment with (ϩ)-pentazocine must start at the onset of disease, as performed in the present study, or whether delayed treatment would prove similarly beneficial. Currently, in vitro studies are under way to determine how (ϩ)-pentazocine regulates genes involved in retinal neuronal apoptosis and will set the stage for elucidating the mechanism of in vivo neuroprotection observed in the present work.
